Opioid use prior to admission for chemotherapy induced febrile neutropenia is associated with increased documented infection, sepsis, and death

Author(s):  
B.B. Eidenschink ◽  
A.E. Stenzel ◽  
Y. Michael ◽  
U.K. Alwahab ◽  
P.C. Kurniali ◽  
...  
2018 ◽  
Vol 25 (6) ◽  
pp. 1381-1387 ◽  
Author(s):  
Abdulkerim Yıldız ◽  
Hacer BA Öztürk ◽  
Murat Albayrak ◽  
Çiğdem Pala ◽  
Osman Şahin ◽  
...  

Background Prophylaxis is strongly recommended in patients with hematological malignancy who are usually at higher risk for infection and neutropenic fever. It is still unclear whether or not there is a definite need for antimicrobial prophylaxis in intermediate-risk hematology patients such as those with lymphoma. Methods A retrospective analysis was made of patients admitted from January 2009 to December 2017 to the Hematology Department of Diskapi Yildirim Beyazit Training and Research Hospital, a tertiary referral hospital in Ankara, Turkey. The study included patients who were diagnosed with any type of lymphoma and given chemotherapy. Routine antimicrobial prophylaxis was administered to 127 lymphoma patients, and not to 65 lymphoma patients. These two groups were compared in respect of the incidence of total infection episodes (IE), febrile neutropenia episodes, and nonneutropenic clinically documented infection episodes. Results For all patients with lymphoma and subtypes of non-Hodgkin lymphoma or Hodgkin lymphoma, no significant difference was determined between the groups in respect of the total incidence of IE, febrile neutropenia and nonneutropenic clinically documented infection both during the first-line chemotherapy and throughout the total follow-up period ( p > 0.05). Patients with prophylaxis had a higher incidence of IE, which was treated with parenteral antibiotics both during the first-line chemotherapy and throughout the total follow-up period ( p < 0.05). Conclusion Antimicrobial prophylaxis was seen to have no effect on the total incidence of infection episode and febrile neutropenia. Therefore, the routine use of antimicrobial prophylaxis should not be recommended for patients with lymphoma.


Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 2041-2041
Author(s):  
Sarah Taimur ◽  
Claudia Nader ◽  
Christine Lloyd-Travaglini ◽  
David C Seldin ◽  
Vaishali Sanchorawala

Abstract Abstract 2041 High dose melphalan and autologous stem cell transplantation (HDM/SCT) can lead to hematologic and organ responses and improved survival in selected patients with AL amyloidosis. Intrinsic and extrinsic risk factors for infections in these patients include functional hyposplenism, hypogammaglobulinemia, melphalan-induced neutropenia, mucositis, and nosocomial exposures. We performed a retrospective review of 493 patients with AL amyloidosis who underwent treatment with HDM/SCT at Boston Medical Center from August 1994 to August 2009. Patients received outpatient treatment from October 1996 onwards. The objectives of this study were to determine the rate of infections, identify infections leading to treatment-related mortality (TRM, defined as death within 100 days), and compare the impact of patient and treatment characteristics on rates of infection. Microbiologically documented infections after HDM/SCT were identified in 119 patients (24%, n=119/493). The median number of days to post- SCT infection was 8 days (range, 0–47). The mean number of days of body temperature more than 100.50 F (38° C) was 3 (95% CI 1.7–4.31). There were 48 deaths (10%) within 100 days of HDM/SCT. Among patients with documented infection, 25 had TRM (21%, n=25/119). Two hundred and forty five patients had febrile neutropenia. One hundred and forty seven of these had negative cultures. Therefore, the rate of culture negative febrile neutropenia was 60% (n=147/245). Identified pathogens included gram positive bacteria (51%), anaerobic bacteria (15%), gram negative bacteria (13%), fungi (8%) and viruses (6%). The majority of these organisms were identified in blood (50%), followed by respiratory secretions (20%) and stool (15%). Of the positive cultures, gram positive infections included staphylococci (29%), streptococci (10%), and enterococci (10%). C. difficile was the most commonly identified anaerobe, accounting for 11% of the total number of positive cultures. Gram negative bacterial infections included enterobacteriacae (8%) and pseudomonas (3%). Fungal infections included candida species (7%), aspergillus (4%) and pneumocystis (1%). Viral infections included herpes (3%), paramyxoviridae (3%) and cytomegalovirus (0.4%). In the unadjusted bivariate analyses, serum creatinine > 2 mg/dL was significantly associated with increased risk of post-HDM/SCT infections (38% versus 21%, p= 0.0007) with an odds ratio (OR) of 2.27 (95% CI 1.40–3.68). In addition, TRM was found to have a significant association with post-HDM/SCT infections (52% versus 21%, p = < 0.0001) with an OR of 3.82 (95% CI 2.01–7.26). The relative risk of TRM in a patient with documented infection was 3.42 (95% CI 2.02–5.79). In multivariate analyses, serum creatinine > 2 mg/dL remained significantly associated with post-SCT infection with an OR of 2.29 (95% CI 1.41–3.73). No significant association was found for age, gender, cardiac involvement, prior steroid therapy, dose of melphalan, time to neutrophil engraftment, number of organs involved in amyloidosis, or dose of infused CD34+ cells, both in unadjusted and adjusted analyses. In conclusion, serum creatinine >2 mg/dL is a risk factor for infections in patients with AL amyloidosis undergoing HDM/SCT. The relative risk of TRM in a patient with a documented infection was 3.34. A broad spectrum of infections, similar to those reported in other SCT patients, is seen in this population. Disclosures: No relevant conflicts of interest to declare.


2021 ◽  
Vol 2021 ◽  
pp. 1-9
Author(s):  
Thanyathorn Jungrungrueng ◽  
Suvaporn Anugulruengkitt ◽  
Supanun Lauhasurayotin ◽  
Kanhatai Chiengthong ◽  
Hansamon Poparn ◽  
...  

Objective. The study aimed to describe the pattern of causative microorganisms, drug susceptibility, risk factors of antibiotic-resistant bacterial infection, and clinical impact of these organisms on pediatric oncology patients with febrile neutropenia. Methods. A retrospective descriptive study of oncologic patients aged less than 15 years who were diagnosed with febrile neutropenia in King Chulalongkorn Memorial Hospital was conducted between January 2013 to December 2017. Characteristics and clinical outcomes of febrile neutropenia episodes, causative pathogens, and their antibiotic susceptibilities were recorded. Result. This study included 267 patients with 563 febrile neutropenia episodes. The median (range) age was 5.1 years (1 month–15 years). The most common underlying disease was acute lymphoblastic leukemia (42.7%). Of 563 febrile episodes, there were 192 (34.1%) with microbiologically documented infection. Among these 192 episodes of microbiologically documented infection, there were 214 causative pathogens: 154 bacteria (72%), 32 viruses (15%), 27 fungus (12.6%), and 1 Mycobacterium tuberculosis (0.4%). Gram-negative bacteria (48.6%) accounted for most of the causative pathogens. Twenty-three percent of them were multidrug resistant, and 18% were carbapenem resistant. Among Gram-positive bacterial infection which accounted for 23.4% of all specimens, the proportion of MRSA was 20%. The 2-week mortality rate was 3.7%. Drug-resistant Gram-negative bacterial infection caused significant adverse events and mortality compared to nonresistant bacterial infection ( p < 0.05 ). Conclusion. There is high rate of drug-resistant organism infection in pediatric oncology patients in a tertiary-care center in Thailand. Infection with drug-resistant Gram-negative bacterial infection was associated with significant morbidity and mortality. Continuous surveillance for the pattern of drug-resistant infections is crucial.


2021 ◽  
pp. 107815522110677
Author(s):  
Whitney J Ly ◽  
Erin E Brown ◽  
Zachary Pedretti ◽  
Jessica Auten ◽  
William S Wilson

Introduction Recent trials have shown early de-escalation of empiric antimicrobial therapy (EAT) in febrile neutropenia has led to less adverse effects with no difference in patient mortality. In 2019, our institution adjusted internal guidelines to de-escalate EAT after 7 days of intravenous anti-pseudomonal therapy in patients with signs of clinical recovery from febrile neutropenia and no evidence of infection. Methods This was a retrospective, single-center, observational, cohort study. Eligible patients were adults with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) who received induction chemotherapy and developed febrile neutropenia without documented infection. Patients were separated based on EAT duration: ≤ 9 days and > 9 days. Empiric antimicrobial therapy was defined as the initiation of an anti-pseudomonal beta-lactam. The primary outcome was the difference in number of EAT-free days. Secondary outcomes included fever recurrence, ICU admissions, fever duration, infections post de-escalation, and Clostridioides difficile infection (CDI). Results Forty-four encounters met inclusion. The EAT ≤ 9 days group had 7 more EAT-free days compared to the EAT > 9 days group (p < 0.001). No between-group differences were identified in terms of fever after EAT discontinuation (p = 0.335), ICU admission (p = 0.498), or CDI (p = 0.498). The EAT > 9 days group experienced longer initial fever (p < 0.001) and received addition of resistant Gram-positive coverage (p = 0.014). More patients receiving EAT > 9 days had a diagnosis of AML (p = 0.001). Conclusions Shorter EAT duration did not lead to worse outcomes in patients with AML or ALL who received induction chemotherapy and developed febrile neutropenia without a documented infection source.


Sign in / Sign up

Export Citation Format

Share Document